NCT07294261

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

A Multicenter, Prospective Clinical Study Evaluating Goselasib Combination Therapy for First-Line Treatment of KRAS G12C Locally Advanced or Metastatic Non-Small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 69 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC

Conditions

• Local Advanced or Metastatic NSCLC

Interventions

Type	Name	Description
DRUG	Garsorasib, Benmelstobart, Anlotinib	Cohort1: Garsorasib RP2D QD D1-21, Benmelstobart 1200 mg IV D1, q21d, Anlotinib 8mg QD, D1-14,q21d. N1=20 participants.
DRUG	Benmelstobart, Anlotinib	Benmelstobart 1200 mg IV D1, q21d, Anlotinib 8mg QD, D1-14,q21d. N2=20 participants.
DRUG	Garsorasib, Cetuximab Beta Injection	Garsorasib 600mg BID, D1, q14d, Cetuximab Beta Injection 500mg/㎡ IV, q14d. N3=20 participants

Timeline

• Start date: 2025-12-23
• Primary completion: 2028-10-30
• Completion: 2028-12-30
• First posted: 2025-12-19
• Last updated: 2025-12-19

Locations

1 site across 1 country: China